Hormone Replacement Therapy Safety in BRCA Carriers After Bilateral Salpingo-Oophorectomy

Safety of HRT Post-RRSO in BRCA Carriers

Short-term use of HRT following RRSO is considered safe among healthy BRCA1/2 mutation carriers who have not had breast cancer 3, 4
Recent evidence suggests HRT is safe for women up to age 45, but beyond that age, there may be an increased risk of breast cancer 1, 5

HRT should be used for the shortest duration possible to control menopausal symptoms 6
The lowest effective dose should be used to minimize potential risks 6
HRT is contraindicated in BRCA mutation carriers who have a personal history of breast cancer 3

Systemic HRT can be used for vasomotor symptoms and to prevent bone loss 1, 5
Local vaginal therapies, including low-dose intravaginal estrogens, may be considered to manage genitourinary symptoms of menopause 1, 5
Topical estrogens to alleviate vaginal dryness may be used with caution due to variable systemic absorption 3, 4
Vaginal moisturizers and lubricants should be prescribed to all women following risk-reducing surgery 3, 4

Regular assessment of clinical risk factors for accelerated bone loss and measurement of bone mineral density is recommended for women who underwent RRSO while premenopausal 1, 5
Resistance and weight-bearing exercise, smoking cessation, reduced alcohol intake, vitamin D and calcium supplements are recommended 1, 5, 4
Antiresorptive therapy should be considered when indicated 1, 5
Premature menopause adversely impacts bone health and potentially cardiovascular health 4, 7

Limitations and risks of HRT should be clearly communicated to patients 1, 5
Appropriate counseling should be available to address psychological distress related to changes in body image and sexuality 3, 4